Equilibrio entre la innovación y el gasto público sanitario: El caso particular de los medicamentos biosimilares
Biosimilar medicines have been commercialized in the European regulatory territory for thirteen years. Its commercialization has not been exempted from multiple criticisms, especially the confusions about its erroneous equivalence with generic medicines and the doubts generated regarding its possibi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://dialnet.unirioja.es/servlet/oaiart?codigo=7671618 |
| Source: | Revista Derecho del Estado, ISSN 0122-9893, Nº. 48 (Enero-Abril), 2021, pags. 273-296 |
| Tags: |
Add Tag
No Tags: Be the first to tag this record
|